{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T08:34:14Z","timestamp":1793090054313,"version":"4.5.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T00:00:00Z","timestamp":1747785600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T00:00:00Z","timestamp":1747785600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Vaccines"],"DOI":"10.1038\/s41541-025-01109-w","type":"journal-article","created":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T17:18:20Z","timestamp":1747847900000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Safety and tolerability of a novel monoclonal antibody cocktail for rabies post-exposure prophylaxis"],"prefix":"10.1038","volume":"10","author":[{"given":"Nidhi","family":"Fotedar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haradanahalli Shankaraiah","family":"Ravish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,21]]},"reference":[{"key":"1109_CR1","doi-asserted-by":"publisher","first-page":"e0006133","DOI":"10.1371\/journal.pntd.0006133","volume":"11","author":"T-Y Chao","year":"2017","unstructured":"Chao, T.-Y. et al. SYN023, a novel humanized monoclonal antibody cocktail, for post-exposure prophylaxis of rabies. PLoS Negl. Trop. Dis. 11, e0006133 (2017).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"1109_CR2","unstructured":"WHO Expert Consultation on Rabies. Third report, technical report series1012. Geneva: World Health Organization; (2018)."},{"key":"1109_CR3","unstructured":"World Health Organization. WHO South East Asia Region: Strategic framework for elimination of human rabies transmitted by dogs in the South\u2013East Asia region. Regional Office for South East Asia, World Health Organization; (2012)."},{"key":"1109_CR4","first-page":"3608","volume":"83","author":"DL Knobel","year":"2005","unstructured":"Knobel, D. L. et al. Re-evaluating the burden of rabies in Africa and Asia. Bull. World Health Organ 83, 3608 (2005).","journal-title":"Bull. World Health Organ"},{"key":"1109_CR5","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.ijid.2005.10.007","volume":"11","author":"Sudarshan","year":"2007","unstructured":"Sudarshan et al. Assessing the burden of human rabies in India: results of a national multi-center epidemiological survey. Int J. Infect. Dis. 11, 29\u201335 (2007).","journal-title":"Int J. Infect. Dis."},{"key":"1109_CR6","unstructured":"Sudarshan M. K. et al. An epidemiological study of animal bites in India: Results of WHO sponsored national"},{"key":"1109_CR7","unstructured":"Zero by 30: the global strategic plan to end human deaths from dog-mediated rabies by 2030. Available at https:\/\/www.who.int\/publications\/i\/item\/9789241513838. Accessed on 30.08.2024."},{"key":"1109_CR8","unstructured":"World Health Organization, World Organization for Animal Health, Food and Agriculture Organization, Global Alliance for Rabies Control,2018. Zero by 30: Global Strategic Plan to end human deaths from dog-mediated rabies by 2030."},{"key":"1109_CR9","unstructured":"Ending the neglect to attain the sustainable development goals: a road map for neglected tropical diseases 2021\u20132030. World Health Organization 2021.Available at https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/332094\/WHO-UCN-NTD-2020.01-eng.pdf. Accessed on 30.08.2024."},{"key":"1109_CR10","unstructured":"World Health Organization. Rabies. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/rabies (Accessed 30 Aug 2024)."},{"key":"1109_CR11","doi-asserted-by":"publisher","first-page":"924","DOI":"10.3390\/microorganisms12050924","volume":"12","author":"D Septelici","year":"2024","unstructured":"Septelici, D., Carbone, G., Cipri, A. & Esposito, S. Management Strategies for Common Animal Bites in Pediatrics: A Narrative Review on the Latest Progress. Microorganisms 12, 924 (2024).","journal-title":"Microorganisms"},{"key":"1109_CR12","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1099\/0022-1317-48-1-105","volume":"48","author":"A Flamand","year":"1980","unstructured":"Flamand, A., Wiktor, T. J. & Koprowski, H. Use of hybridoma monoclonal antibodies in the detection of antigenic differences between rabies and rabies-related virus proteins. II. The glycoprotein. J. Gen. Virol. 48, 105\u2013109 (1980).","journal-title":"J. Gen. Virol."},{"key":"1109_CR13","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1096\/fj.12-219964","volume":"27","author":"L Both","year":"2013","unstructured":"Both, L. et al. Production, characterization, antigenic specificity of recombinant 62-71-3, a candidate monoclonal antibody for rabies prophylaxis in humans. FASEB J. 27, 2055\u20132065 (2013).","journal-title":"FASEB J."},{"key":"1109_CR14","doi-asserted-by":"publisher","first-page":"e0256779","DOI":"10.1371\/journal.pone.0256779","volume":"16","author":"PK Kim","year":"2021","unstructured":"Kim, P. K. et al. A broad-spectrum and highly potent human monoclonal antibody cocktail for rabies prophylaxis. PLoS ONE 16, e0256779 (2021).","journal-title":"PLoS ONE"},{"key":"1109_CR15","doi-asserted-by":"publisher","first-page":"e2722","DOI":"10.1093\/cid\/ciaa779","volume":"73","author":"K Kansagra","year":"2021","unstructured":"Kansagra, K. et al. A Phase 3, Randomized, Open-label, Noninferiority Trial Evaluating Anti-Rabies Monoclonal Antibody Cocktail (TwinrabTM) Against Human Rabies Immunoglobulin (HRIG). Clin. Infect. Dis. 73, e2722\u2013e2728 (2021).","journal-title":"Clin. Infect. Dis."},{"key":"1109_CR16","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1093\/cid\/cix791","volume":"66","author":"NJ Gogtay","year":"2018","unstructured":"Gogtay, N. J. et al. Comparison of a Novel Human RabiesMonoclonal Antibody to Human Rabies Immunoglobulin for Postexposure Prophylaxis: A Phase 2\/3, Randomized, Single-Blind, Noninferiority, Controlled Study. Clin. Infect. Dis. 66, 387\u2013395 (2018).","journal-title":"Clin. Infect. Dis."},{"key":"1109_CR17","first-page":"e52163","volume":"16","author":"A Manna","year":"2024","unstructured":"Manna, A. et al. Real-World Safety of TwinRab, the World\u2019s First Novel Cocktail of Rabies Monoclonal Antibodies, in a Clinical Setting. Cureus 16, e52163 (2024).","journal-title":"Cureus"},{"key":"1109_CR18","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s44149-021-00023-7","volume":"1","author":"HK Tiwari","year":"2021","unstructured":"Tiwari, H. K., Gogoi-Tiwari, J. & Robertson, I. D. Eliminating dog-mediated rabies: challenges and strategies. Anim. Dis. 1, 19 (2021).","journal-title":"Anim. Dis."},{"key":"1109_CR19","doi-asserted-by":"publisher","first-page":"443","DOI":"10.4103\/ijcm.ijcm_562_23","volume":"49","author":"MP Tambe","year":"2024","unstructured":"Tambe, M. P. et al. Post-Marketing Surveillance of the World\u2019s First Novel Cocktail of Rabies Monoclonal Antibodies: TwinRab\u2122 in Real \\-World Setting. Indian J. Community Med 49, 443\u2013447 (2024).","journal-title":"Indian J. Community Med"},{"key":"1109_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-13527-0","volume":"12","author":"M Ejemel","year":"2022","unstructured":"Ejemel, M. et al. A cocktail of human monoclonal antibodies broadly neutralizes North American rabies virus variants as a promising candidate for rabies post-exposure prophylaxis. Sci. Rep. 12, 9403 (2022).","journal-title":"Sci. Rep."},{"key":"1109_CR21","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1097\/00000441-200207000-00004","volume":"324","author":"M Berger","year":"2002","unstructured":"Berger, M., Shankar, V. & Vafai, A. Therapeutic Applications of Monoclonal Antibodies. Am. J. Med Sci. 324, 14\u201330 (2002).","journal-title":"Am. J. Med Sci."}],"container-title":["npj Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01109-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01109-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01109-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T17:18:27Z","timestamp":1747847907000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01109-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,21]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1109"],"URL":"https:\/\/doi.org\/10.1038\/s41541-025-01109-w","relation":{},"ISSN":["2059-0105"],"issn-type":[{"value":"2059-0105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,21]]},"assertion":[{"value":"8 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"102"}}